Newsletter Signup x
Diffuse Midline Gliomas (DMGs) are aggressive childhood brain tumours, which include diffuse intrinsic pontine gliomas (DIPG). There is currently no cure. A class of cancer drugs, called MEK inhibitors, have shown early promise in treating some DMGs but there is a risk that these tumours could develop resistance to these drugs. Prof. Chris Jones and his team aim to work out the mechanisms by which DMG cells become resistant to MEK inhibitors and come up with new combination treatments to overcome this.
Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma
Prof. Chris Jones
Institute of Cancer Research
Sutton, SM2 5NG
1 April 2021
30 months
£349,393
Patient Story – Ellie B
Ellie was diagnosed with Hodgkin Lymphoma in 2019 when she was 16 years old. Now at 21 years old,
Read moreBrain Tumour Awareness Month blog: The Voice of 30
Imagine a child and all their school friends being diagnosed with a brain tumour at the same time; it is
Read more